Get the Stockscreener App
1.11
0.00%
0.00
After Hours:
1.12
0.01
+0.90%
Humacyte Inc stock is traded at $1.11, with a volume of 7.25M.
It is up +0.00% in the last 24 hours and down -5.13% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.11
Open:
$1.128
24h Volume:
7.25M
Relative Volume:
1.33
Market Cap:
$207.87M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.0374
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-15.27%
1M Performance:
-5.13%
6M Performance:
-52.97%
1Y Performance:
-67.92%
1-Day Range:
$1.10
$1.16
1-Week Range:
$1.0601
$1.30
52-Week Range:
$1.0601
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.11 | 207.87M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Can Humacyte Inc. Equity Warrant stock maintain growth trajectoryJuly 2025 Institutional & Entry Point Confirmation Signals - ulpravda.ru
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - Bölüm Sonu Canavarı
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Is Humacyte Inc. Equity Warrant stock a contrarian buy2025 Breakouts & Breakdowns & Safe Capital Growth Plans - DonanımHaber
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - ulpravda.ru
Published on: 2025-12-19 01:36:49 - Улправда
Is Humacyte Inc. Equity Warrant stock affected by interest rate hikesCEO Change & Reliable Breakout Forecasts - Улправда
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Aug Chart Watch: Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterInsider Buying & Capital Efficient Trading Techniques - ulpravda.ru
Humacyte enters sales agreement with TD Securities - MSN
Humacyte's US$28m Market Cap Fall Books Insider Losses - simplywall.st
Humacyte Enters Sales Agreement with TD Securities - TipRanks
Humacyte may offer and sell shares of common stock of up to $60 million from time to time through TD Cowen, acting as agent - marketscreener.com
Humacyte (NASDAQ: HUMA) details $60M at the market stock offering - Stock Titan
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Investment Review: Is Humacyte Inc Equity Warrant stock a contrarian buyJuly 2025 Short Interest & Expert Curated Trade Setups - moha.gov.vn
Humacyte secures up to $77.5 million credit facility with Avenue Capital - Investing.com Nigeria
Humacyte secures $77.5 million loan facility - MSN
Humacyte announces credit facility of up to $77.5 million with Avenue Capital - marketscreener.com
Humacyte Signs $77.5 Million Credit Facility - marketscreener.com
Humacyte Secures $77.5 Million Credit Facility with Avenue Venture Opportunities Fund to Support Growth and Development Initiatives - Quiver Quantitative
Press Release: Humacyte Announces Credit Facility of Up to $77.5 Million With Avenue Capital - 富途牛牛
Humacyte Terminates Revenue Interest Agreement - The Globe and Mail
Total debt per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView — Track All Markets
Humacyte Secures $77.5 Million Loan Facility - TipRanks
[8-K] Humacyte, Inc. Reports Material Event | HUMA SEC FilingForm 8-K - Stock Titan
Humacyte terminates revenue interest purchase agreement - marketscreener.com
Humacyte (NASDAQ: HUMA) to issue 5.7M shares, pay $38M to end deal - Stock Titan
Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to "Hold" - MarketBeat
Is Humacyte Inc a good long term investmentStraddle and Strangle Trades & Explosive Capital Growth Plans - earlytimes.in
Humacyte (HUMA): Benchmark remains bullish on stock - MSN
Humacyte Stock (HUMA) Opinions on FDA Approval for Symvess Product - Quiver Quantitative
Humacyte (HUMA): Benchmark Remains Bullish on Stock - Finviz
11 Best Micro-Cap Stocks to Invest in According to Analysts - Insider Monkey
Humacyte prices 28.4M shares at $2.11 in registered direct offering - MSN
Market Moves: Can Humacyte Inc stock weather global recessionPortfolio Risk Report & Reliable Intraday Trade Plans - moha.gov.vn
Bond Watch: Will Humacyte Inc Equity Warrant stock pay special dividendsJuly 2025 Volume & Low Volatility Stock Recommendations - BỘ NỘI VỤ
Book value per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest? - Finviz
How Humacyte Inc. Equity Warrant stock reacts to global recession fearsBuy Signal & High Accuracy Buy Signal Tips - Newser
Can Humacyte Inc. stock continue upward trendPortfolio Growth Summary & Momentum Based Trading Signals - Newser
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates - MSN
Humacyte, Inc.'s (NASDAQ:HUMA) largest shareholders are retail investors with 57% ownership, institutions own 26% - Yahoo Finance
Will Humacyte Inc. stock maintain growth storyForecast Cut & High Accuracy Trade Alerts - Newser
Can Humacyte Inc. stock maintain growth trajectoryMarket Volume Summary & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
Humacyte (HUMA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Humacyte stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
What drives Humacyte Inc stock priceGap Up/Gap Down Analysis & Collaborate and Win Together - earlytimes.in
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):